Clinical trial
An Open-Label Comparison of Duloxetine to Other Alternatives for the Management…
NCT00385671 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00385671 |
|---|---|
| Title | An Open-Label Comparison of Duloxetine to Other Alternatives for the Management of Diabetic Peripheral Neuropathic Pain |
| Official title | An Open-Label, Randomized Comparison of Duloxetine, Pregabalin, and the Combination of Duloxetine and Gabapentin Among Patients With Inadequate Response to Gabapentin for the Management of Diabetic Peripheral Neuropathic Pain |
| Lead sponsor | Eli Lilly and Company, Industry |
| Collaborators | Boehringer Ingelheim Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Diabetic Neuropathy, Painful |
| Intervention type | Drug |
| Interventions | duloxetine hydrochloride, pregabalin, gabapentin |
| Enrollment | 407 |
| Start date | Sep 1, 2006 |
| Primary completion | Aug 1, 2009 |
| Completion | Nov 1, 2009 |
| First posted | Oct 11, 2006 |
| Last update posted | Jul 26, 2011 |
| Countries | Germany, United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: